Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

543 ARTÍCULOS , VIENDO DEL 406 AL 420

Potential Roles of Extracellular Vesicles as Diagnosis Biomarkers and Therapeutic Approaches for Cognitive Impairment in Alzheimer's Disease

Shi Y, Bao Q, Chen W, Wang L, Peng D, Liu J, Liu Q, Zhang Y, Ji Z, Shen A.

J Alzheimers Dis. 2022;87(1):1-15. doi: 10.3233/JAD-215666.

Advances in aptamers against Aβ and applications in Aβ detection and regulation for Alzheimer's disease

Zheng Y, Zhang L, Zhao J, Li L, Wang M, Gao P, Wang Q, Zhang X, Wang W.

Theranostics. 2022 Jan 31;12(5):2095-2114. doi: 10.7150/thno.69465. eCollection 2022.

Early-stage Alzheimer disease: getting trial-ready

Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R.

Nat Rev Neurol. 2022 Jul;18(7):389-399. doi: 10.1038/s41582-022-00645-6. Epub 2022 Apr 4.

Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study

Pomilio C, Pérez NG, Calandri I, Crivelli L, Allegri R; ADNI Alzheimer’s Disease Neuroimaging Initiative; Sevlever G, Saravia F.

Geroscience. 2022 Jun;44(3):1791-1805. doi: 10.1007/s11357-022-00568-6. Epub 2022 Apr 20.

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A.

J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.

Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

Ossenkoppele R, van der Kant R, Hansson O.

Lancet Neurol. 2022 Aug;21(8):726-734. doi: 10.1016/S1474-4422(22)00168-5. Epub 2022 May 25.

Effects of interventions on cerebral perfusion in the Alzheimer's disease spectrum: A systematic review

Marcolini S, Frentz I, Sanchez-Catasus CA, Mondragon JD, Feltes PK, van der Hoorn A, Borra RJH, Ikram MA, Dierckx RAJO, De Deyn PP.

Ageing Res Rev. 2022 Aug;79:101661. doi: 10.1016/j.arr.2022.101661. Epub 2022 Jun 4.

Alzheimer Disease

McDade EM.

Continuum (Minneap Minn). 2022 Jun 1;28(3):648-675. doi: 10.1212/CON.0000000000001131.

Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer's disease

Vandendriessche C, Kapogiannis D, Vandenbroucke RE.

Adv Drug Deliv Rev. 2022 Nov;190:114486. doi: 10.1016/j.addr.2022.114486. Epub 2022 Aug 8.

Exploring Plausible Therapeutic Targets for Alzheimer's Disease using Multi-omics Approach, Machine Learning and Docking

Parvathy Dharshini SA, Sneha NP, Yesudhas D, Kulandaisamy A, Rangaswamy U, Shanmugam A, Taguchi YH, Gromiha MM.

Curr Top Med Chem. 2022;22(22):1868-1879. doi: 10.2174/1568026622666220902110115.

Demand Coupling Drives Neurodegeneration: A Model of Age-Related Cognitive Decline and Dementia

Turknett J, Wood TR.

Cells. 2022 Sep 7;11(18):2789. doi: 10.3390/cells11182789.

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects

Villain N, Planche V, Levy R.

Rev Neurol (Paris). 2022 Dec;178(10):1011-1030. doi: 10.1016/j.neurol.2022.06.012. Epub 2022 Sep 29.

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA.

JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias